Veterans Department at The Mesothelioma Center Names New Director
Decorated U.S. Army Capt. Aaron Munz has joined The Mesothelioma Center and Asbestos.com as the new director of the advocacy group's Veterans Department. He was drawn by the opportunity to serve those with whom he once served so proudly. Munz, who received the Bronze Star Medal for Valor in 2004 during Operation Iraqi Freedom, has begun assisting military veterans diagnosed with asbestos-related diseases. He retired from active duty in 2007 after serving nine years in combat and strategic training, but he never lost the desire to work toward a common good. "My professional career has been focused on service, and helpi...
Source: Asbestos and Mesothelioma News - June 25, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Veterans & Military Source Type: news

Asbestos Victims Committee Rejects Garlock Bankruptcy Plan
The committee of asbestos personal injury claimants in the ongoing bankruptcy case of Garlock Sealing Technologies (GST) is urging asbestos victims to reject the company's second amended reorganization plan. The committee is comprised of 12 asbestos victims, represented by their attorneys, who were appointed by the bankruptcy court that will determine whether the plan to restructure the business can move forward. The plan under debate would include $489.5 million to settle past and future claims over the next 40 years. It would cap the asbestos liability for Garlock and fundamentally change any future litiga...
Source: Asbestos and Mesothelioma News - June 23, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Legislation, Laws & Litigation Source Type: news

Study Finds Mice with Mesothelioma Live Longer on Aspirin, According...
New findings at one of the nation’s top mesothelioma research centers suggest that aspirin may have a valuable role to play in the fight against deadly malignant pleural mesothelioma.(PRWeb June 18, 2015)Read the full story at http://www.prweb.com/releases/2015/06/prweb12791625.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 19, 2015 Category: Pharmaceuticals Source Type: news

Immunotherapy with Surgery Raises Hopes for Mesothelioma Patients
An immunotherapy vaccine by itself won't stop malignant pleural mesothelioma, but its ability to enhance the effectiveness of cytoreductive surgery could become the treatment breakthrough that doctors and patients have been seeking for years. The combination of immunotherapy and surgery, which proved especially effective in preclinical research at the University of Pennsylvania, should add to the multimodal treatment approach that includes chemotherapy and radiation for mesothelioma patients. "It is very promising," renowned thoracic surgeon and mesothelioma specialist Dr. Sunil Singhal, of the Abra...
Source: Asbestos and Mesothelioma News - June 18, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Disparities Discovered Among Blacks, Whites with Mesothelioma
This study suggests that further attention to the treatment of black patients is needed to determine if patient survival would be improved with better access to the same treatments as whites," the authors write. "Further studies on exposure history, access to care, type of medical and surgical treatment, and hospital characteristics in black patients with MPM are needed." (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - June 17, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

New Report Links Protein with Mesothelioma Survival and Chemotherapy...
Researchers say the amount of a tumor suppressor protein called p16 found in mesothelioma tissue samples is directly related to survival.(PRWeb June 14, 2015)Read the full story at http://www.prweb.com/releases/2015/06/prweb12786150.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2015 Category: Pharmaceuticals Source Type: news

Ochsner Launches Mesothelioma Patient Assistance Fund
The renowned Ochsner Cancer Institute in New Orleans inaugurated its Mesothelioma Patient Assistance Fund — the first mesothelioma-specific fund at a major cancer center in the Southeast. The fund will provide much-needed financial relief for patients diagnosed with this asbestos-related disease. Patients coming to Ochsner for pleural or peritoneal mesothelioma treatment will be eligible for up to $1,500 in assistance to help cover expenses for them and their families. The funds may be used for travel, housing, meals, medication or various emergency needs related to care. Ochsner has carved a niche in r...
Source: Asbestos and Mesothelioma News - June 11, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Mayo Clinic Radio: Mesothelioma/Hypoactive Sexual Desire Disorder/Senior Nutrition
Malignant mesothelioma, cancer of the lining of the lungs and abdomen, is relatively rare but often fatal. The 5-year survival rate is between just 5 and 10 percent. On this week's program, thoracic surgeon Dr. Dennis Wigle and pulmonary and critical care medicine specialist Dr. Tobias Peikert explain how viruses are being used to treat mesothelioma and [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 8, 2015 Category: Databases & Libraries Source Type: news

Bevacizumab May Be Next Standard of Care for Mesothelioma
Discussions About Mesothelioma at ASCO Meeting There were other abstracts involving mesothelioma presented at the ASCO, adding even more optimism about potential treatment advances. Dr. Raffit Hassan, mesothelioma specialist from the National Cancer Institute, detailed results of a phase I trial involving immunotherapy drug CRS-207 in combination with standard chemotherapy. Disease control was obtained in 30 of the 32 trial participants. There was partial response in 19 patients and stable disease in 11. CRS-207 is given by vaccination. Median duration of response was 5 months and median progression-free survi...
Source: Asbestos and Mesothelioma News - June 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Surgery Extends Survival for Pleural Mesothelioma Patients
Thoracic surgeon and mesothelioma specialist Dr. Andrea Wolf likes to use the analogy that you don't need a randomized trial to know that skydivers with a parachute generally will fare better than those jumping without one. She compares it to surgery for patients with pleural mesothelioma. You don't need a randomized trial to know that surgical patients will do better than non-surgical ones. "Unfortunately, surgery is still an ongoing controversy with mesothelioma, about whether you should have it. I hear that a lot," Dr. Wolf of Mount Sinai Hospital in New York City told Asbestos.com. "But taking all thing...
Source: Asbestos and Mesothelioma News - June 3, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Paradigm-Changing Triplet Therapy for MesotheliomaParadigm-Changing Triplet Therapy for Mesothelioma
Bevacizumab added to standard of care provided significantly longer overall survival for patients with malignant pleural mesothelioma. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mr. Fluffy Asbestos Disclosure Burdens Real Estate Agents
The ongoing Mr. Fluffy asbestos insulation debacle in Australia is placing a heavy burden on unprepared real estate agents who must disclose if the homes they sell contain the deadly substance. Real estate agents in the Australian Capital Territory (ACT), where more than 1,000 homes in Canberra were identified to contain asbestos, are obligated by law to disclose the presence of asbestos or face fines of $1 million or more. But in New South Wales (NSW), where more than a dozen homes showed asbestos contamination, officials say real estate agents and property managers have no clear guidelines. Thousands more homes may be af...
Source: Asbestos and Mesothelioma News - June 1, 2015 Category: Environmental Health Authors: Lorraine Kember Tags: Legislation, Laws & Litigation Source Type: news

Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma
(Pharmamar) PharmaMar today announced data from the Phase 2 ATREUS study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2 percent of patients treated with the anticancer drug trabectedin in second line were alive and free of progression at 12 weeks. The median progression-free survival in these 17 evaluated patients was 8.3 weeks. The study will be presented at the 2015 ASCO Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2015 Category: Cancer & Oncology Source Type: news

Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer
Roche announced today phase III results from a collaborative group study that showed that patients with malignant pleural mesothelioma, a rare type of cancer that affects the lining of the lungs, lived significantly longer when treated with Avastin in combination with standard therapy (pemetrexed and cisplatin chemotherapy) compared to standard therapy alone. (Source: Roche Investor Update)
Source: Roche Investor Update - May 30, 2015 Category: Pharmaceuticals Source Type: news

Impressive Survival Time for Peritoneal Mesothelioma Patients
The prognosis for patients with peritoneal mesothelioma has improved considerably in recent years, leaving behind the pessimism that often still engulfs those with pleural mesothelioma. The survival-time gap between peritoneal and pleural — the two most common types of mesothelioma cancer — has grown significantly wider with advances in therapy. According to a recent study done at Wake Forest University School of Medicine in Winston-Salem, North Carolina, the median survival for a peritoneal patient is more than four times that of a patient diagnosed with pleural mesothelioma. "The take-home message here ...
Source: Asbestos and Mesothelioma News - May 29, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

New NIOSH Report Finds Higher Mesothelioma Risk Among Nuclear Workers,...
People who have worked at nuclear weapons facilities are more likely than the general public to eventually develop malignant pleural mesothelioma.(PRWeb May 28, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12750212.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 29, 2015 Category: Pharmaceuticals Source Type: news

Inflammatory Claims About Inflammation
We all appreciate the elegance of simple solutions to complex problems. But we know too that simplicity can often masquerade as truth, hiding a more nuanced reality. Such is the case with inflammation, where pseudoscience, exaggerated claims, false promises, and dangerous oversimplification have dominated for too long. Here is a typical missive: "Inflammation controls our lives. Have you or a loved one dealt with pain, obesity, ADD/ADHD, peripheral neuropathy, diabetes, heart disease, stroke, migraines, thyroid issues, dental issues, or cancer? If you answered yes to any of these disorders you are dealing with inflam...
Source: Science - The Huffington Post - May 29, 2015 Category: Science Source Type: news

New Report Highlights Current and Emerging Biomarkers for...
Researchers say the future looks bright for more effective mesothelioma diagnosis and treatment planning with biomarkers.(PRWeb May 27, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12744932.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 27, 2015 Category: Pharmaceuticals Source Type: news

Researchers Say Surgery May Restore Effectiveness of Immunotherapy for...
A new study suggests that having cytoreductive surgery can make immunotherapy more effective for patients with advanced mesothelioma.(PRWeb May 26, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12744763.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 26, 2015 Category: Pharmaceuticals Source Type: news

Russia, India Block Proposal to Restrict Asbestos Exports
For the fifth consecutive time, a handful of countries blocked a United Nations proposal that effectively would have restricted the exportation of dangerous chrysotile asbestos. Russia, India, Pakistan, Zimbabwe, Kazakhstan, Cuba and Kyrgyzstan stopped the proposal to put the toxic mineral on the Rotterdam Convention Hazardous Substances list, which would have tightened shipping regulations and likely reduced the spread of asbestos. Although an overwhelming majority of countries represented last week in Geneva, Switzerland, backed the U.N. proposal, there was no unanimous consensus, which the Rotterdam Convention require...
Source: Asbestos and Mesothelioma News - May 20, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Legislation, Laws & Litigation Source Type: news

ADAO 2015: Asbestos Awareness at the Forefront
Over the past few years, I've been fortunate enough to attend the Asbestos Disease Awareness Organization's (ADAO) annual International Asbestos Awareness Conference. In 2010, ADAO Co-founder Linda Reinstein asked me to speak and share my story of my experience with asbestos and mesothelioma. I always say Linda gave me my voice; it was Linda who believed in me and saw I had passion for awareness and a story to tell. Over the last few years, Linda has become a mentor to me and a dear friend. She even attended my 9th annual Lungleavin' Day celebration this past February. I was so happy when Linda reached out to my husband Ca...
Source: Healthy Living - The Huffington Post - May 16, 2015 Category: Consumer Health News Source Type: news

Study Finds UK Must Improve Mesothelioma Care
The United Kingdom needs a more universal, multidisciplinary approach to the treatment of malignant pleural mesothelioma to improve survival times and overcome the no-hope attitude that too often surrounds this diagnosis. Researchers in the U.K. analyzed 8,740 mesothelioma cases from England and Wales over a five-year period and found a startling variation in how doctors manage the disease, sparking a call for more experienced specialty centers to treat it. Researchers also estimated that the incidence of mesothelioma will continue to rise in the U.K. until it peaks in 2020, despite the decades-long decline in the use an...
Source: Asbestos and Mesothelioma News - May 16, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Recent Research Points to Immunotherapy as Promising New Mesothelioma...
New studies on drugs that fight cancer by altering the immune system suggest that they may offer the best new hope for the treatment of malignant mesothelioma.(PRWeb May 15, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12724110.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 15, 2015 Category: Pharmaceuticals Source Type: news

Fish Oil Supplements Could Harm Cancer Patients
Taking common fish oil supplements — or even eating a particular fish — may reduce the effectiveness of chemotherapy for cancer patients, including those with malignant mesothelioma, according to a new study. Doctors and scientists from the Netherlands Cancer Institute in Amsterdam last month found clear, tumor resistance to chemotherapy in pre-clinical models. They determined fish oil can be detrimental. "We currently advise our [cancer] patients not to take fish oil in the days surrounding chemotherapy treatment," lead researcher, Dr. Laura van Hussen-Daenen, told Asbestos.com. "Fish oil supple...
Source: Asbestos and Mesothelioma News - May 14, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

PharmaMar announces new advances in oncology at ASCO 2015 for compounds YONDELIS® and PM1183
(Pharmamar) PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS® and PM1183 highlighting data in small cell lung cancer, soft tissue sarcoma, and mesothelioma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2015 Category: Cancer & Oncology Source Type: news

Immunotherapy Clinical Trial Opens in Chicago
Internationally recognized mesothelioma specialist Dr. Hedy Kindler is recruiting patients for what could become a groundbreaking clinical trial at the University of Chicago Medicine's Comprehensive Cancer Center. Her expectations are high. There are 90 different clinical trials in various stages around the country today testing pembrolizumab — the hottest new immunotherapy cancer drug — but only one trial involves malignant mesothelioma. The University of Chicago has it. "This is really exciting," she told the Mesothelioma Applied Research Foundation last month. "This is an exciting class ...
Source: Asbestos and Mesothelioma News - May 8, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Researchers Say “Unprecedented” Mesothelioma Response Possible with...
Scientists presenting at the recent annual meeting of the American Association for Cancer Research say a monoclonal antibody used to treat skin cancer stopped or reversed mesothelioma tumor growth in...(PRWeb May 06, 2015)Read the full story at http://www.prweb.com/releases/2015/05/prweb12698981.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 7, 2015 Category: Pharmaceuticals Source Type: news

Woman Wins $13M for Deadly Asbestos in Talcum Powder
A California woman won a $13 million lawsuit against Colgate-Palmolive after a jury determined she developed mesothelioma from asbestos in the company's Cashmere Bouquet talcum powder. Judith Winkel, 73, told the court she used the popular scented talcum powder from 1961 to 1976. It wasn't until 1973 that federals laws required commercial talcum products to be asbestos-free. Although researchers have debated the connection between talc and cancer for years, last week's verdict was the first against Colgate-Palmolive for asbestos exposure from commercial talcum powder. Talc, one of the world's softest minerals, has been min...
Source: Asbestos and Mesothelioma News - May 5, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Legislation, Laws & Litigation Source Type: news

Alarming Spike in Imported Asbestos Products in Canada
The importation of asbestos into Canada increased by a startling 22 percent in 2014, raising safety concerns for the unsuspecting general public and those still working with the toxic products. Brake pads and brake linings were the most popular asbestos import, valued at a seven-year high of $3.6 million, according to The Globe and Mail news service research. Other related imports included various friction materials, compressed asbestos fiber jointing and shipments of crocidolite fibers — the most dangerous form of asbestos. Much of the findings came from Statistics Canada, a government website that provides economic...
Source: Asbestos and Mesothelioma News - May 1, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Asbestos Exposure & Bans Source Type: news

Study Finds New Regimen May Ward Off Skin Rash from Common...
Doctors say a new dosing regimen may make it easier for mesothelioma patients to avoid an uncomfortable side effect of chemotherapy.(PRWeb April 28, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12681257.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 28, 2015 Category: Pharmaceuticals Source Type: news

Powerful Skin Cancer Drug Stops Mesothelioma Tumor Growth
A groundbreaking immunotherapy drug that effectively treats skin cancer stopped tumor growth in 76 percent of patients diagnosed with malignant pleural mesothelioma, a recent study shows. Researchers at the University of Pennsylvania School of Medicine reported their findings involving pembrolizumab, a drug marketed under the brand name Keytruda, earlier this week at the American Association of Cancer Research (AACR) annual meeting in Philadelphia. Twenty-five patients with mesothelioma whose disease had progressed after receiving first-line or standard chemotherapy participated in the study. Researchers administered pembr...
Source: Asbestos and Mesothelioma News - April 27, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

'Unprecedented' Disease Control in Mesothelioma Trial'Unprecedented' Disease Control in Mesothelioma Trial
The immunotherapy pembrolizumab looked very promising for the treatment of this rare form of lung cancer in an early-stage trial. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Asbestos in Schools, Hospitals Puts Children and Doctors at Risk
When Heather Karras learned the Alabama elementary school her children attend contains asbestos, she pulled them out — and asked for answers. Delayed responses from Bay Minette Elementary School officials raised fears the deteriorating 1920s-era school possibly was placing children, teachers and anyone else who visits the building at risk of asbestos exposure. Asbestos causes mesothelioma, an often terminal cancer that affects nearly 3,000 people annually in the U.S. “What did I do?” Karras told Asbestos.com. “I thought we moved here to have a better life at this old hometown school. I made the wors...
Source: Asbestos and Mesothelioma News - April 24, 2015 Category: Environmental Health Authors: Beth Swantek Tags: Asbestos Exposure & Bans Source Type: news

Asbestos in Schools, Hospitals Puts Children and Doctors at Risk
When Heather Karras learned the Alabama elementary school her children attend contains asbestos, she pulled them out — and asked for answers. Delayed responses from Bay Minette Elementary School officials raised fears the deteriorating 1920s-era school possibly was placing children, teachers and anyone else who visits the building at risk of asbestos exposure. Asbestos causes mesothelioma, an often terminal cancer that affects nearly 3,000 people annually in the U.S. “What did I do?” Karras told Asbestos.com. “I thought we moved here to have a better life at this old hometown school. I made the wors...
Source: Asbestos and Mesothelioma News - April 24, 2015 Category: Environmental Health Tags: Asbestos Exposure & Bans Source Type: news

Mesothelioma Patients Live Longer After Aggressive Cancer Surgery
Aggressive pleurectomy/decortication surgery, while often recommended, will cause a significant decrease in pulmonary function with early-stage mesothelioma patients whose symptoms were previously minimal. More symptomatic patients with advanced disease will experience an improved quality of life and a preservation of their current pulmonary status after the same surgery. Those findings were reported in a study from the Department of Surgery, Division of Oncology at the University of Chicago Medical Center, raising questions about aggressive surgery for the early stages of mesothelioma. "Some of the results might be a...
Source: Asbestos and Mesothelioma News - April 23, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Upcoming Mesothelioma Symposium Will Focus on Latest Research
Renowned specialist and thoracic surgeon Dr. Robert Cameron, who has pioneered many of the worldwide treatment advances in recent years, will host the 5th Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma on May 2. The symposium will be held at the LeMeridien Delfina in Santa Monica, California, close to the UCLA Mesothelioma Comprehensive Research Program, where Cameron serves as director. Although the symposium is designed for physicians, nurses, oncologists, radiologists and pulmonologists, it also will be open to patients, families and anyone wanting to learn more about the latest advancements in t...
Source: Asbestos and Mesothelioma News - April 21, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

Investigational personalized cellular therapy tolerated well by patients with advanced mesothelioma, ovarian and pancreatic cancers
Genetically modified versions of patients’ own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers. The data adds to a growing body of research showing the promise of CAR T cell technology. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 20, 2015 Category: Science Source Type: news

Immunotherapy drug pembrolizumab shows early promise for mesothelioma patients
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study. Patients diagnosed with the disease, which is tied to exposure to asbestos, have a median survival rate of about one year. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 20, 2015 Category: Science Source Type: news

Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Dateline City: PHILADELPHIA KEYTRUDA Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Merck’s Innovative Basket Trial in 20 Cancers PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in 25 patients with advanced pleural mesothelioma, a difficu...
Source: Merck.com - Product News - April 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news

Investigational personalized cellular therapy tolerated well by patients
(University of Pennsylvania School of Medicine) Genetically modified versions of patients' own immune cells successfully traveled to tumors they were designed to attack in an early-stage trial for mesothelioma and pancreatic and ovarian cancers at the Perelman School of Medicine at the University of Pennsylvania. The data adds to a growing body of research showing the promise of CAR T cell technology. The interim results will be presented at the American Association for Cancer Research Annual Meeting 2015, April 18-22. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2015 Category: Cancer & Oncology Source Type: news

Penn Medicine: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients
(University of Pennsylvania School of Medicine) The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 19, 2015 Category: Cancer & Oncology Source Type: news

Asbestos Forces Young Family from Their 'Mr. Fluffy Home'
On a sunny afternoon in the Australian capital city of Canberra, Katie Williams and Daniel Lawrence brought their newborn son, Hugh, home from the hospital. Like any new parents, they were excited, especially because Hugh was the “miracle” in vitro fertilization baby they had longed for. The pair placed Hugh’s baby carrier on the porch outside the front door and snapped photos to mark the occasion. Then Williams broke down, bursting into tears. Despite welcoming a newborn into their lives and their home, it was not the family homecoming they wished for. Four years after purchasing the property, the couple...
Source: Asbestos and Mesothelioma News - April 17, 2015 Category: Environmental Health Tags: Asbestos Exposure & Bans Source Type: news

AstraZeneca's tremelimumab receives FDA approval to treat mesothelioma
British-Swedish drugmaker AstraZeneca has obtained orphan drug designation from the US Food and Drug Administration (FDA) for its anti-CTLA-4 monoclonal antibody, tremelimumab to treat malignant mesothelioma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 17, 2015 Category: Pharmaceuticals Source Type: news

Apple Is Bringing Clinical Trials to Your Fingertips
Trusting smartphone apps to help manage the details of life is commonplace in this digital age. There are dozens of applications on multiple platforms that help users manage their finances, schedule appointments and control their weight. Now, one of the biggest app developers in the world wants to revolutionize how our devices manage disease and possibly provide better outcomes. Apple recently launched ResearchKit, a digital tool equipped with iPhone apps created specifically for medical research. The first five ResearchKit apps include: Parkinson mPower Share the Journey (for breast cancer) GlucoSuccess (for diabetes) A...
Source: Asbestos and Mesothelioma News - April 16, 2015 Category: Environmental Health Tags: Research & Clinical Trials Source Type: news

New UK Findings Show Location Matters When it Comes to Mesothelioma...
A newly published study finds significant differences in mesothelioma outcomes in cancer centers that see fewer cases.(PRWeb April 15, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12648996.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 15, 2015 Category: Pharmaceuticals Source Type: news

New Clinical Trial Shows Promise for Life-Extending Mesothelioma Drug
Dr. Michele Maio at the University Hospital of Siena in Italy doesn't need to wait for results of the ongoing, multicenter, worldwide clinical trial involving the latest immunotherapy drug for malignant mesothelioma. He already is a believer. Maio and his colleagues in the oncology department recently published results of their smaller, one-center study detailing the effectiveness of tremelimumab, a drug that helps the body's own immune system to destroy mesothelioma cells without harming healthy ones. Tremelimumab, which is given intravenously, essentially unmasks the tumor cells and unleashes the immune system to do its ...
Source: Asbestos and Mesothelioma News - April 13, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

FDA Approves New Use for Immunotherapy Drug in Mesothelioma Treatment
The U.S. Food and Drug Administration (FDA) granted orphan drug designation last week to the immunotherapy vaccine CRS-207, moving it one step closer to changing the way malignant pleural mesothelioma is treated. CRS-207 is derived from Listeria monocytogenes, a bacterium that causes the serious infection listeriosis. For the vaccine, the bacteria are weakened and genetically modified to produce an anti-tumor response without causing disease. Early results are impressive. The vaccine produced a 94 percent rate of disease control, either partial response or stable disease, according to a presentation made at the latest Inte...
Source: Asbestos and Mesothelioma News - April 7, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Japanese Team Proposes New Prognostic Index for Mesothelioma,...
Scientists in Japan say they have come up with a more reliable way to predict prognosis in newly-diagnosed malignant pleural mesothelioma patients.(PRWeb April 06, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12632709.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news

New Mesothelioma Treatment Options Are Emerging for Patients
Although no definitive cure is in sight, the treatment of malignant pleural mesothelioma has entered a promising, much-anticipated phase that goes beyond the multimodal approach that has been the standard of care at specialty centers for the past several years. There is new hope on the horizon. Thoracic surgeon and renowned mesothelioma specialist Dr. Robert Cameron, along with scientist Raymond Wong, Ph.D., and thoracic and cardia surgeon Dr. Svetlana Kotova, recently detailed the changing face of therapy in a paper they co-authored and published in the Cancer Management Research Journal . "With all the ongoing r...
Source: Asbestos and Mesothelioma News - April 2, 2015 Category: Environmental Health Authors: Tim Povtak Tags: Treatment & Doctors Source Type: news

Orphan Drug Approval May Mean New Treatment Option for Mesothelioma,...
A company that produces a cancer vaccine called CRS-207 has been granted orphan drug status for the treatment of malignant mesothelioma, potentially opening new treatment possibilities for patients...(PRWeb April 01, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12617988.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 1, 2015 Category: Pharmaceuticals Source Type: news